Erratum to 'Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients': [ESMO Open Volume 7, Issue 1, February 2022, 100393] [0.03%]
关于“palbociclib与质子泵抑制剂之间的药物相互作用可能显著影响转移性乳腺癌患者的临床结局”的回复的勘误:[ESMO开放获取期刊 第7卷,第1期,2022年2月,100393]
R Beechinor,A Palumbo,H K Chew et al.
R Beechinor et al.
Published Erratum
ESMO open. 2022 Apr;7(2):100460. DOI:10.1016/j.esmoop.2022.100460 2022
Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes [0.03%]
肺癌大规模人群中的激酶基因间断裂重排及其在现实世界临床结局中的特征分析
Y Yao,Z Yu,Y Ma et al.
Y Yao et al.
Background: Kinase gene fusions are strong driver mutations in neoplasia; however, kinase intergenic-breakpoint rearrangements (IGRs) confound the detection of such fusions and of targeted treatments. We aim to provide an...
Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers [0.03%]
阿特朱单抗治疗多种晚期实体瘤的II期多队列研究
J Tabernero,F Andre,J-Y Blay et al.
J Tabernero et al.
Background: The programmed death-ligand 1 inhibitor atezolizumab had shown clinical activity against several advanced malignancies. Patients and methods: ...
Clinical Trial
ESMO open. 2022 Apr;7(2):100419. DOI:10.1016/j.esmoop.2022.100419 2022
Comparison of S1 antibody titers between BNT162b2 and ChAdOx1 COVID-19 vaccination in cancer patients [0.03%]
癌症患者中BNT162b2和ChAdOx1新冠疫苗诱导的S1抗体滴度比较研究
P A van Dam,Y Debie,L Teuwen et al.
P A van Dam et al.
Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers [0.03%]
一项关于血管紧张素生成抑制剂在晚期胆道癌、结直肠癌和卵巢癌中的血管反应标准的等位基因轨迹研究
C Zhou,J OConnor,A Backen et al.
C Zhou et al.
Background: Vascular endothelial growth factor inhibitors (VEGFi) are compromised by a lack of validated biomarkers. Previously we showed that changes in the concentration of plasma Tie2 (pTie2) was a response biomarker f...
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN [0.03%]
度伐利尤单抗联合或不联合特瑞普利尤单抗以及依托泊苷-铂类用于广泛期小细胞肺癌一线治疗的3年总生存随访:CASPIAN研究
L Paz-Ares,Y Chen,N Reinmuth et al.
L Paz-Ares et al.
Background: In the phase III CASPIAN study, first-line durvalumab in combination with etoposide plus either cisplatin or carboplatin (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage sma...
Randomized Controlled Trial
ESMO open. 2022 Apr;7(2):100408. DOI:10.1016/j.esmoop.2022.100408 2022
Outcomes of patients with cancer infected with SARS-CoV-2: results from the Ion Chiricuţă Oncology Institute series [0.03%]
SARS-CoV-2感染肿瘤患者的预后:克里楚特ゥ肿瘤研究所系列研究结果
A Preda,T Ciuleanu,P Kubelac et al.
A Preda et al.
Background: The evolution of COVID-19 is a controversial topic in cancer patients. They have been designated by international organizations as a vulnerable population at greater risk for contracting SARS-CoV-2 and having ...
"The first ones now, will later be last": understanding the importance of historical context when reading ESMO-MCBS scores [0.03%]
“后来者居上”——解读ESMO-MCBS评分时须知的历史背景的重要性
N I Cherny,U Dafni,G Pentheroudakis et al.
N I Cherny et al.
Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials [0.03%]
赫赛汀和拉帕替丁新辅助治疗HER2阳性早期乳腺癌患者后生存率:随机对照试验的meta分析研究
V Guarneri,G Griguolo,F Miglietta et al.
V Guarneri et al.
Background: Studies testing the addition of lapatinib to neoadjuvant trastuzumab + chemotherapy reported an increase in pathologic complete response (pCR), with, nevertheless, discordant results in terms of survival, main...
Current standards and practice changing studies in genitourinary (GU) cancers-a review of studies in localized/early GU cancers [0.03%]
泌尿生殖系统(GU)肿瘤的现行标准及有变革意义的研究——局部早期GU肿瘤相关研究述评
W C Tan,R Kanesvaran
W C Tan
Optimizing treatment of genitourinary cancers in the early-stage setting continues to remain an area of need, given that the development of distant metastases is often the life-limiting factor in the natural history of these cancers. The us...